Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149915 · ClinicalTrials.gov registry record · Phase 1
Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias
A Phase 1 study, sponsored by Threshold Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01149915 is a Phase 1 study that has completed, run by Threshold Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT01149915, a Phase 1 study, has completed, sponsored by Threshold Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose, dose limiting toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase chronic myelogenous leukemia (CML), high risk myelodysplastic syndromes, advanced myelofibrosis or relapsed/refractory chronic lymphocytic leukemia (CLL).
Interventions
- DRUG TH-302
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01149915
The ClinicalTrials.gov registry entry for NCT01149915 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Threshold Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TH-302 is the first listed.
NCT01149915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01149915 about?
NCT01149915 is a clinical study titled "Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias". The primary objective of this study is to determine the maximum tolerated dose, dose limiting toxicity, safety and tolerability of TH-302 in patients with acute leukemias, advanced phase chronic myelogenous leukemia (CML), high risk myelodysplastic syndromes, advanced myelofibrosis or relapsed/refra...
What is the current status of trial NCT01149915?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-06. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01149915?
The interventions under investigation include: TH-302 (DRUG).
Who is sponsoring clinical trial NCT01149915?
This trial is sponsored by Threshold Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.